Abstract
The orally active nonpeptide gonadotropin-releasing hormone (GnRH)-receptor antagonist relugolix (Relumina) is being developed by Takeda and ASKA Pharmaceutical as a treatment for various sex hormone related disorders. Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids, and studies evaluating the efficacy of the drug as treatment for endometriosis-associated pain and prostate cancer are currently underway. This article summarizes the milestones in the development of relugolix leading to this first approval for the treatment of symptoms associated with uterine fibroids.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Dose-Response Relationship, Drug
-
Drug Approval
-
Endometriosis / drug therapy
-
Female
-
Hormone Antagonists / administration & dosage
-
Hormone Antagonists / adverse effects
-
Hormone Antagonists / pharmacokinetics
-
Hormone Antagonists / therapeutic use*
-
Humans
-
Japan
-
Leiomyoma / drug therapy*
-
Male
-
Middle Aged
-
Phenylurea Compounds / administration & dosage
-
Phenylurea Compounds / adverse effects
-
Phenylurea Compounds / pharmacokinetics
-
Phenylurea Compounds / therapeutic use*
-
Prostatic Neoplasms / drug therapy
-
Pyrimidinones / administration & dosage
-
Pyrimidinones / adverse effects
-
Pyrimidinones / pharmacokinetics
-
Pyrimidinones / therapeutic use*
-
Receptors, LHRH / antagonists & inhibitors*
-
Treatment Outcome
Substances
-
Hormone Antagonists
-
Phenylurea Compounds
-
Pyrimidinones
-
Receptors, LHRH
-
relugolix